Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Harriet Stanwix
Ask the experts: the potential of tyrosine kinase inhibitors in oncology
In this ‘Ask the Experts’ feature, we spoke to a panel of experts working throughout the field of oncology to gain an insight into their current perspectives on the challenges and benefits of tyrosine kinase inhibitors (TKI). We discuss the role that tyrosine kinases play in tumor biology, if there are factors that affect TKI selection for patients, what the side effects are and how our experts believe TKIs will develop over the next 5 years.
AACR22: NK cells show promise as a possible lymphoma treatment
Results from a Phase I/II trial have demonstrated that natural killer (NK) cells derived from cord blood, which were activated and complexed with a CD30/CD16A bispecific antibody, elicited a 89% overall response rate in patients with relapsed or refractory CD30+ lymphoma. The findings were recently presented at the AACR 2022 Annual Meeting (8−13 April 2022; LA, USA).
Survey results demonstrate patient satisfaction with Somatuline® Autogel®/Somatuline® Depot (lanreotide)
Data from two patient surveys, PRESTO2 and HomeLAN, has demonstrated patient-reported benefits for those administering Somatuline® Autogel®/Somatuline® Depot (lanreotide). The findings were presented at the 19th Annual ENETS Conference, 10−11 March 2022 (Barcelona, Spain). PRESTO2 was an e-survey, investigating injection site pain in those living with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) or acromegaly (n=219 and n=85).
NICE recommends the PARP inhibitor niraparib for ovarian cancer treatment via the NHS
A PARP inhibitor, termed Zejula® (niraparib), has been endorsed for routine use in the NHS by the National Institute for Health Care and Excellence (NICE, UK) to treat some forms of ovarian, peritoneal or fallopian tube cancer. Niraparib is a capsule to be taken once daily. It will be available for those with various forms of fallopian tube, ovarian or peritoneal cancer who meet specific criteria.
Gene editing used to test novel preclinical model for pig to human kidney transplant
A study at the University of Alabama at Birmingham conducted the first successful clinical-grade transplant of gene edited pig kidneys into a human recipient using a novel human preclinical model. A study from the University of Alabama at Birmingham (UAB; AL, USA) has reported the first successful clinical-grade transplant of pig kidneys into a human recipient in the American Journal of Transplantation.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Harriet
Contact Harriet, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack